A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide - 04/12/23
, Marinda Meertens b, Frederiek M.F. van Ooijen c, Esther Oomen-de Hoop a, Evert de Jonge c, Marieke J.H. Coenen c, Andries M. Bergman d, Stijn L.W. Koolen a, e, Ronald de Wit a, Alwin D.R. Huitema b, f, g, Ron H.N. van Schaik c, Ron H.J. Mathijssen aAbstract |
Extragonadal androgens play a pivotal role in prostate cancer disease progression on androgen receptor signaling inhibitors (ARSi), including abiraterone and enzalutamide. We aimed to investigate if germline variants in genes involved in extragonadal androgen synthesis contribute to resistance to ARSi and may predict clinical outcomes on ARSi. We included ARSi naive metastatic prostate cancer patients treated with abiraterone or enzalutamide and determined 18 germline variants in six genes involved in extragonadal androgen synthesis. Variants were tested in univariate and multivariable analysis for the relation with overall survival (OS) and time to progression (TTP) by Cox regression, and PSA response by logistic regression. A total of 275 patients were included. From the investigated genes CYP17A1, HSD3B1, CYP11B1, AKR1C3, SRD5A1 and SRD5A2, only rs4736349 in CYP11B1 in homozygous form (TT), present in 54 patients (20%), was related with a significantly worse OS (HR = 1.71, 95% CI 1.09 – 2.68, p = 0.019) and TTP (HR = 1.50, 95% CI 1.08 – 2.09, p = 0.016), and was related with a significantly less frequent PSA response (OR = 0.48, 95% CI 0.24 – 0.96, p = 0.038) on abiraterone or enzalutamide in a multivariable analysis. The frequent germline variant rs4736349 in CYP11B1 is, as homozygote, an independent negative prognostic factor for treatment with abiraterone or enzalutamide in ARSi naive metastatic prostate cancer patients. Our findings warrant prospective investigation of this potentially important predictive biomarker.
Le texte complet de cet article est disponible en PDF.Highlights |
• | A germline variant in CYP11B1 is related to response to abiraterone or enzalutamide. |
• | In homozygous form, this germline variant is related with worse outcomes of treatment. |
• | With a global prevalence of 20%, the homozygous variant is highly frequent. |
Keywords : Abiraterone, Enzalutamide, Germline variant, CYP11B1, Prostate cancer, Clinical outcome
Plan
Vol 169
Article 115890- décembre 2023 Retour au numéro
Article précédent
- Adjunctive use of oral MAF is associated with no disease progression or mortality in hospitalized patients with COVID-19 pneumonia: The single-arm COral-MAF1 prospective trial
- Lucrezia Spadera, Marina Lugarà, Maria Spadera, Mariano Conticelli, Gabriella Oliva, Vincenzo Bassi, Valentina Apuzzi, Francesco Calderaro, Olimpia Fattoruso, Pietro Guzzi, Maurizio D’Amora, Oriana Catapano, Roberta Marra, Maria Galdo, Michele Zappalà, Toshio Inui, Martin Mette, Giuseppe Vitiello, Maria Corvino, Giuseppe Tortoriello
- Parthenolide alleviates cognitive dysfunction and neurotoxicity via regulation of AMPK/GSK3β(Ser9)/Nrf2 signaling pathway
- Jinfeng Sun, Liwei Li, Li Xiong, Fan Chen, Lingyu She, Hao Tang, Yuqing Zeng, Ying Duan, Luyao Li, Wei Wang, Gao Li, Xia Zhao, Guang Liang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?